1. Home
  2. BCIC vs VRCA Comparison

BCIC vs VRCA Comparison

Compare BCIC & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCIC

BCP Investment Corporation

HOLD

Current Price

$7.10

Market Cap

86.9M

Sector

Finance

ML Signal

HOLD

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$5.06

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCIC
VRCA
Founded
2006
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
86.9M
88.0M
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
BCIC
VRCA
Price
$7.10
$5.06
Analyst Decision
Hold
Buy
Analyst Count
2
2
Target Price
$9.00
$17.00
AVG Volume (30 Days)
54.3K
104.1K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
14.14%
N/A
EPS Growth
262.50
N/A
EPS
N/A
N/A
Revenue
N/A
$35,577,000.00
Revenue This Year
$0.00
N/A
Revenue Next Year
N/A
$94.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
370.22
52 Week Low
$6.70
$3.28
52 Week High
$13.50
$9.82

Technical Indicators

Market Signals
Indicator
BCIC
VRCA
Relative Strength Index (RSI) 29.11 47.80
Support Level $6.92 $4.52
Resistance Level $7.84 $5.94
Average True Range (ATR) 0.12 0.40
MACD -0.08 0.04
Stochastic Oscillator 3.23 43.60

Price Performance

Historical Comparison
BCIC
VRCA

About BCIC BCP Investment Corporation

BCP Investment Corp is an externally managed, non-diversified closed-end investment company. The company invests in secured term loans, bonds or notes and mezzanine debt in privately-held middle market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt and selected equity investments in privately-held middle market companies.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: